In consequence, the first ex vivo gene therapy receiving marketing authorization in Europe in 2016 was that for ADA-SCID, a very rare severe combined immunodeficiency (SCID) caused by a deficiency of adenosine desaminase (ADA).53 Here, ADA is linked to severe combined immunodeficiency.